Aro Biotherapeutics
Email
Email
X
X
Bluesky
Bluesky
FASEB Autoimmunity Conference
Novel CD71 Centyrin-based siRNA therapeutic targeting the CD40 pathway for autoimmune disorders
A PDF of poster being presented by Dr. Gomez-Atria can be accessed by clicking the button below or on Aro's website.
More
Novel CD71 Centyrin-based siRNA therapeutic targeting the CD40 pathway for autoimmune disorders
Information
Presenting at: Poster Session 2 - Wednesday, July 30th 7:40 pm to 9:40 pm Short Talk - Thursday, July 31st 10:25 am to 10:40 am
More
Information
Presenter
More About Aro!
Aro Biotherapeutics | Targeted Genetic Medicine | United States
Aro Biotherapeutics | Targeted Genetic Medicine | United States
Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins.
Newsroom
Newsroom
Latest News
Scientific Publications
Scientific Publications
Follow Us on Linkedin!
Follow Us on Linkedin!
Aro Biotherapeutics | 6,668 followers on LinkedIn. | Unlocking the Potential of Genetic Medicines Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
previous
next
View on mobile